Loading company…
Venus MedTech develops catheter-based artificial heart valves, including the VenusA valve line, to treat aortic stenosis.
Founded in 2009 and based in Hangzhou, China, Venus MedTech (HangZhou) Inc. develops the percutaneous interventional heart valve system (TAVR), including VenusA-Valve, VenusA-Plus and VenusA-Pro. The company closed a venture funding round in May 2018 and listed on the Hong Kong Stock Exchange in December 2019 under stock code 02500. The company is at the Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in